Contribution of bone tissue modulus to breast cancer metastasis to bone

Cancer Microenvironment

Volumn 4, Issue 3, 2011, Pages 247-259

  Guelcher, Scott A ^a,b   Sterling, Julie A ^b,c,d  

^a VANDERBILT UNIVERSITY   (United States)

^b VANDERBILT UNIVERSITY MEDICAL CENTER   (United States)

^c DEPARTMENT OF VETERANS AFFAIRS   (United States)

^d VANDERBILT UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

Breast cancer; Mechanotransduction; Modulus; PTHrP; Rigidity; Tumor induced bone disease

Indexed keywords

DENOSUMAB; FASUDIL; FIBRONECTIN; INTEGRIN; MITOGEN ACTIVATED PROTEIN KINASE; OSTEOCLAST DIFFERENTIATION FACTOR; OSTEOPONTIN; PARATHYROID HORMONE RELATED PROTEIN; PROTEIN TYROSINE KINASE; RHO KINASE; TRANSCRIPTION FACTOR GLI2; TRANSCRIPTION FACTOR RUNX2; TRANSFORMING GROWTH FACTOR BETA; TRANSFORMING GROWTH FACTOR BETA RECEPTOR 3; VITRONECTIN; VITRONECTIN RECEPTOR;

ANTINEOPLASTIC ACTIVITY; BONE DESTRUCTION; BONE METASTASIS; BONE MICROENVIRONMENT; BONE MINERALIZATION; BRAIN VASOSPASM; BREAST CANCER; CELL ADHESION; CELL CONTACT; CYTOSKELETON; DRUG TARGETING; EXTRACELLULAR MATRIX; EXTRACELLULAR MATRIX RIGIDITY; FOCAL ADHESION; FORCE; GENE; GENE EXPRESSION; GLI2 GENE; HUMAN; MECHANICAL FORCE; MECHANOTRANSDUCTION; METASTASIS INHIBITION; MICROENVIRONMENT; NONHUMAN; OSTEOLYSIS; PARATHYROID HORMONE RELATED PROTEIN GENE; PRIORITY JOURNAL; PROTEIN EXPRESSION; PROTEIN PHOSPHORYLATION; PULMONARY HYPERTENSION; REVIEW; TUMOR CELL; YOUNG MODULUS;

EID: 84856467831     PISSN: 18752292     EISSN: 18752284     Source Type: Journal    
DOI: 10.1007/s12307-011-0078-3     Document Type: Review

References (128)

1. Fizazi K, Carducci M, Smith M, Damiao R, Brown J, Karsh L, Milecki P, ShoreN,RaderM,WangH, JiangQ,TadrosS,DanseyR, Goessl C (2011) Denosumab versus zoledronic acid for treatment of bone metastases in men with castration-resistant prostate cancer: a randomised, double-blind study. Lancet 377:813-822
2. Guise TA, Mundy GR (1998) Cancer and bone. Endocr Rev 19:18-54 (Pubitemid 29122073)
3. Yoneda T, Sasaki A, Mundy GR (1994) Osteolytic bone metastasis in breast cancer. Breast Canc Res Treat 32:73-84 (Pubitemid 24322250)
4. Ruppender NS, Merkel AR, Martin TJ, Mundy GR, Sterling JA, Guelcher SA (2010) Matrix rigidity induces osteolytic gene expression of metastatic breast cancer cells. PLoS One 5:e15451
5. Sterling JA, Edwards JR, Martin TJ, Mundy GR (2011) Advances in the biology of bone metastasis: how the skeleton affects tumor behavior. Bone 48:6-15
6. Johnson RW, Nguyen MP, Padalecki SS, Grubbs BG, Merkel AR, Oyajobi BO, Matrisian LM, Mundy GR, Sterling JA (2011) Tgf-β promotion of gli2 induced pthrp expression is independent of canonical hedgehog signaling. Cancer Res
7. Sterling JA, Wu L, Banerji SS (2006) Parp regulates tgf-beta receptor type ii expression in estrogen receptor-positive breast cancer cell lines. Anticancer Res 26:1893-1901 (Pubitemid 43989447)
8. Ko Y, Koli KM, Banerji SS, Li W, Zborowska E, Willson JK, Brattain MG, Arteaga CL (1998) A kinase-defective transforming growth factor-beta receptor type ii is a dominantnegative regulator for human breast carcinoma mcf-7 cells. Int J Oncol 12:87-94
9. Ko Y, Banerji SS, Liu Y, Li W, Liang J, Soule HD, Pauley RJ, Willson JK, Zborowska E, Brattain MG (1998) Expression of transforming growth factor-beta receptor type ii and tumorigenicity in human breast adenocarcinoma mcf-7 cells. J Cell Physiol 176:424-434 (Pubitemid 28319726)
10. Guise TA (2000) Molecular mechanisms of osteolytic bone metastases. Cancer 88:2892-2898 (Pubitemid 30413169)
11. Yin JJ, Selander K, Chirgwin JM, Dallas M, Grubbs BG, Wieser R, Massague J, Mundy GR, Guise TA (1999) Tgf-beta signaling blockade inhibits pthrp secretion by breast cancer cells and bone metastases development. J Clin Invest 103:197-206 (Pubitemid 29053137)
12. Kakonen SM, Selander KS, Chirgwin JM, Yin JJ, Burns S, Rankin WA, Grubbs BG, Dallas M, Cui Y, Guise TA (2002) Transforming growth factor-beta stimulates parathyroid hormone-related protein and osteolytic metastases via smad and mitogen-activated protein kinase signaling pathways. J Biol Chem 277:24571-24578 (Pubitemid 34951984)
13. Powell GJ, Southby J, Danks JA, Stillwell RG, Hayman JA, Henderson MA, Bennett RC, Martin TJ (1991) Localization of parathyroid hormone-related protein in breast cancer metastases: increased incidence in bone compared with other sites. Cancer Res 51:3059061
14. Southby J, Kissin MW, Danks JA, Hayman JA, Moseley JM, Henderson MA, Bennett RC, Martin TJ (1990) Immunohistochemical localization of parathyroid hormone-related protein in human breast cancer. Cancer Res 50:7710-7716
15. Sterling JA, Oyajobi BA (2006) The hedgehog signaling molecule gli2 induces parathyroid hormone-related peptide expression and osteolysis in metastatic human breast cancer cells. Cancer Res 66:7548-7553 (Pubitemid 44289210)
16. Guise T, Yin J, Taylor S, Kumagai Y, Dallas M, Boyce B, Yoneda T, Mundy G (1996) Evidence for a causal role of parathyroid hormone-related protein in the pathogenesis of human breast cancer-mediated osteolysis. J Clin Invest 98:1544-1549 (Pubitemid 26327863)
17. Pratap J, Javed A, Languino LR, van Wijnen AJ, Stein JL, Stein GS, Lian JB (2005) The runx2 osteogenic transcription factor regulates matrix metalloproteinase 9 in bone metastatic cancer cells and controls cell invasion. Mol Cell Biol 25:8581-8591 (Pubitemid 41369178)
18. Javed A, Barnes GL, Pratap J, Antkowiak T, Gerstenfeld LC, van Wijnen AJ, Stein JL, Lian JB, Stein GS (2005) Impaired intranuclear trafficking of runx2 (aml3/cbfa1) transcription factors in breast cancer cells inhibits osteolysis in vivo. Proc Natl Acad Sci USA 102:1454-1459 (Pubitemid 40209191)
19. Bendre MS, Margulies AG (2005) Tumor-derived interleukin- 8 stimulates osteolysis independent of the receptor activator of nuclear factor-kappab ligand pathway. Cancer Res 65:11001-11009 (Pubitemid 41713370)
20. Bendre MS, Montague DC, Peery T, Akel NS, Gaddy D, Suva LJ (2003) Interleukin-8 stimulation of osteoclastogenesis and bone resorption is a mechanism for the increased osteolysis of metastatic bone disease. Bone 33:28-37 (Pubitemid 36952685)
21. Gallwitz WE, Guise TA (2002) Guanosine nucleotides inhibit different syndromes of pthrp excess caused by human cancers in vivo. J Clin Invest 110:1559-1572 (Pubitemid 35396925)
22. Broadus AE, Mangin M, Ikeda K, Insogna KL, Weir EC, Burtis WJ, Stewart AF (1988) Humoral hypercalcemia of cancer. Identification of a novel parathyroid hormone-like peptide. N Engl J Med 319:556-563
23. Lanske B, Amling M, Neff L, Guiducci J, Baron R, Kronenberg HM (1999) Ablation of the pthrp gene or the pth/pthrp receptor gene leads to distinct abnormalities in bone development. J Clin Invest 104:399-407 (Pubitemid 29534324)
24. Wysolmerski JJ, Philbrick WM, Dunbar ME, Lanske B, Kronenberg H, Broadus AE (1998) Rescue of the parathyroid hormone-related protein knockout mouse demonstrates that parathyroid hormone-related protein is essential for mammary gland development. Development 125:1285-1294 (Pubitemid 28203943)
25. VanHouten JN, Wysolmerski JJ (2003) Low estrogen and high parathyroid hormone-related peptide levels contribute to accelerated bone resorption and bone loss in lactating mice. Endocrinology 144:5521-5529 (Pubitemid 37476082)
26. Yamamoto M, Harm SC, Grasser WA, Thiede MA (1992) Parathyroid hormone-related protein in the rat urinary bladder: a smooth muscle relaxant produced locally in response to mechanical stretch. Proc Natl Acad Sci USA 89:5326-5330
27. Noda M, Katoh T, Takuwa N, Kumada M, Kurokawa K, Takuwa Y (1994) Synergistic stimulation of parathyroid hormone-related peptide gene expression by mechanical stretch and angiotensin ii in rat aortic smooth muscle cells. J Biol Chem 269:17911-17917 (Pubitemid 24206182)
28. Pirola CJ,Wang HM, StrgacichMI, Kamyar A, Cercek B, Forrester JS, Clemens TL, Fagin JA (1994) Mechanical stimuli induce vascular parathyroid hormone-related protein gene expression in vivo and in vitro. Endocrinology 134:2230-2236 (Pubitemid 24142967)
29. Thiede MA, Daifotis AG, Weir EC, Brines ML, Burtis WJ, Ikeda K, Dreyer BE, Garfield RE, Broadus AE (1990) Intrauterine occupancy controls expression of the parathyroid hormonerelated peptide gene in preterm rat myometrium. Proc Natl Acad Sci USA 87:6969-6973
30. Ito M, Ohtsuru A, Enomoto H, Ozeki S, Nakashima M, Nakayama T, Shichijo K, Sekine I, Yamashita S (1994) Expression of parathyroid hormone-related peptide in relation to perturbations of gastric motility in the rat. Endocrinology 134:1936-1942 (Pubitemid 24110758)
31. Tanaka N, Ohno S, Honda K, Tanimoto K, Doi T, Ohno-Nakahara M, Tafolla E, Kapila S, Tanne K (2005) Cyclic mechanical strain regulates the pthrp expression in cultured chondrocytes via activation of the ca2+ channel. J Dent Res 84:64-68 (Pubitemid 43822064)
32. Chen X, Macica CM, Ng KW, Broadus AE (2005) Stretchinduced pth-related protein gene expression in osteoblasts. J Bone Miner Res 20:1454-1461 (Pubitemid 41033529)
33. Dallas SL, Miyazono K, Skerry TM, Mundy GR, Bonewald LF (1995) Dual role for the latent transforming growth factor-beta binding protein in storage of latent tgf-beta in the extracellular matrix and as a structural matrix protein. J Cell Biol 131:539-549
34. Young MF (2003) Bone matrix proteins: their function, regulation, and relationship to osteoporosis. Osteoporos Int 14(Suppl 3):S35-S42
35. Yoneda T (2000) Cellular and molecular basis of preferential metastasis of breast cancer to bone. J Orthop Sci 5:75-81 (Pubitemid 30133795)
36. van der P, Vloedgraven H, Papapoulos S, Lowick C, Grzesik W, Kerr J, Robey PG (1997) Attachment characteristics and involvement of integrins in adhesion of breast cancer cell lines to extracellular bone matrix components. Lab Invest 77:665-675 (Pubitemid 28018788)
37. Liapis H, Flath A, Kitazawa S (1996) Integrin alpha v beta 3 expression by bone-residing breast cancer metastases. Diagn Mol Pathol 5:127-135
38. McCabe NP, De S, Vasanji A, Brainard J, Byzova TV (2007) Prostate cancer specific integrin alphavbeta3 modulates bone metastatic growth and tissue remodeling. Oncogene 26:6238-6243 (Pubitemid 47414368)
39. Townsend PA, Villanova I, Uhlmann E, Peyman A, Knolle J, Baron R, Teti A, Horton MA (2000) An antisense oligonucleotide targeting the alphav integrin gene inhibits adhesion and induces apoptosis in breast cancer cells. Eur J Cancer 36:397-409 (Pubitemid 30116738)
40. Gillespie MT, Thomas RJ, Pu ZY, Zhou H, Martin TJ, Findlay DM (1997) Calcitonin receptors, bone sialoprotein and osteopontin are expressed in primary breast cancers. Int J Canc 73:812-815 (Pubitemid 127483032)
41. Schneider JG, Amend SR, Weilbaecher KN (2011) Integrins and bone metastasis: integrating tumor cell and stromal cell interactions. Bone 48:54-65
42. Nakamura I, le Duong T, Rodan SB, Rodan GA (2007) Involvement of alpha(v)beta3 integrins in osteoclast function. J Bone Miner Metab 25:337-344 (Pubitemid 350063834)
43. Pecheur I, Peyruchaud O, Serre CM, Guglielmi J, Voland C, Bourre F, Margue C, Cohen-Solal M, Buffet A, Kieffer N, Clezardin P (2002) Integrin alpha(v)beta3 expression confers on tumor cells a greater propensity to metastasize to bone. FASEB J 16:1266-1268
44. Sloan EK, Pouliot N, Stanley KL, Chia J, Moseley JM, Hards DK, Anderson RL (2006) Tumor-specific expression of alphavbeta3 integrin promotes spontaneous metastasis of breast cancer to bone. Breast Canc Res 8:R20
45. Zhao Y, Bachelier R, Treilleux I, Pujuguet P, Peyruchaud O, Baron R, Clement-Lacroix P, Clezardin P (2007) Tumor alphavbeta3 integrin is a therapeutic target for breast cancer bone metastases. Cancer Res 67:5821-5830 (Pubitemid 46985016)
46. Sterling JA, Guelcher SA (2011) Bone structural components regulating sites of tumor metastasis. Curr Osteoporos Rep
47. Van der Velde-Zimmermann D, Verdaasdonk MA, Rademakers LH, De Weger RA, Van den Tweel JG, Joling P (1997) Fibronectin distribution in human bone marrow stroma: matrix assembly and tumor cell adhesion via alpha5 beta1 integrin. Exp Cell Res 230:111-120 (Pubitemid 27187546)
48. Takayama S, Ishii S, Ikeda T, Masamura S, Doi M, Kitajima M (2005) The relationship between bone metastasis from human breast cancer and integrin alpha(v)beta3 expression. Anticancer Res 25:79-83 (Pubitemid 40470094)
49. Geiger B, Bershaksky A (2002) Exploring the neighborhood: adhesion-coupled cell mechanotransducers. Cell 110:139-143
50. Moore SW, Roca-Cusachs P, Sheetz MP (2010) Stretchy proteins on stretchy substrates: the important elements of integrinmediated rigidity sensing. Dev Cell 19:194-206
51. Paszek MJ, Zahir N, Johnson KR, Lakins JN, Rozenberg GI, Gefen A, Reinhart-King CA, Margulies SS, Dembo M, Boettiger D, Hammer DA, Weaver VM (2005) Tensional homeostasis and the malignant phenotype. Cancer Cell 8:241-254 (Pubitemid 41317594)
52. Paszek MJ, Weaver VM (2004) The tension mounts: mechanics meets morphogenesis and malignancy. J Mammary Gland Biol Neoplasia 9:325-342 (Pubitemid 41149140)
53. Huang SJ, Ingber DE (2005) Cell tension, matrix mechanics, and cancer development. Cancer Cell 8:175-176 (Pubitemid 41317587)
54. Reijnders CM, Bravenboer N, Tromp AM, Blankenstein MA, Lips P (2007) Effect of mechanical loading on insulin-like growth factor-i gene expression in rat tibia. J Endocrinol 192:131-140 (Pubitemid 46444403)
55. Mantila Roosa SM, Liu Y, Turner CH (2011) Gene expression patterns in bone following mechanical loading. J Bone Miner Res 26:100-112
56. Hochmuth RM (2000) Micropipette aspiration of living cells. J Biomech 33:15-22
57. Jiang G, Huang AH, Cai Y, Tanase M, Sheetz MP (2006) Rigidity sensing at the leading edge through alphavbeta3 integrins and rptpalpha. Biophys J 90:1804-1809
58. Saez A, Buguin A, Silberzan P, Ladoux B (2005) Is the mechanical activity of epithelial cells controlled by deformations or forces? Biophys J 89:L52-L54 (Pubitemid 41725585)
59. Discher DE, Janmey P, Wang YL (2005) Tissue cells feel and respond to the stiffness of their substrate. Science 310:1139-1143 (Pubitemid 41681732)
60. Katsumi A, Orr AW, Tzima E, Schwartz MA (2004) Integrins in mechanotransduction. J Biol Chem 279:12001-12004 (Pubitemid 38445760)
61. Harjanto D, Zaman MH (2010) Matrix mechanics and receptorligand interactions in cell adhesion. Org Biomol Chem 8:299-304
62. Luo BH, Carman CV, Springer TA (2007) Structural basis of integrin regulation and signaling. Annu Rev Immunol 25:619-647 (Pubitemid 46697919)
63. Humphries JD, Byron A, Humphries MJ (2006) Integrin ligands at a glance. J Cell Sci 119:3901-3903 (Pubitemid 44650863)
64. Berrier AL, Yamada KM (2007) Cell-matrix adhesion. J Cell Physiol 213:565-573 (Pubitemid 350058247)
65. den Hertog J, Pals CE, Peppelenbosch MP, Tertoolen LG, de Laat SW, Kruijer W (1993) Receptor protein tyrosine phosphatase alpha activates pp 60c-src and is involved in neuronal differentiation. EMBO J 12:3789-3798 (Pubitemid 23282755)
66. Na S, Collin O, Chowdhury F, Tay B, Ouyang M, Wang Y, Wang N (2008) Rapid signal transduction in living cells is a unique feature of mechanotransduction. Proc Natl Acad Sci USA 105:6626-6631 (Pubitemid 351754557)
67. Zheng XM, Resnick RJ, Shalloway D (2000) A phosphotyrosine displacement mechanism for activation of src by ptpalpha. EMBO J 19:964-978 (Pubitemid 30119822)
68. Schmidt C, Pommerenke H, Durr F, Nebe B, Rychly J (1998) Mechanical stressing of integrin receptors induces enhanced tyrosine phosphorylation of cytoskeletally anchored proteins. J Biol Chem 273:5081-5085 (Pubitemid 28108667)
69. Kakonenea SM (2005) Transforming growth factor beta stimulates parathyroid hormone related protein an dosteolytic metastases via smad and mapk signaling pathways. J Biol Chem 227
70. Wang N, Butler JP, Ingber DE (1993) Mechanotransduction across the cell surface and through the cytoskeleton. Science 260:1124-1127 (Pubitemid 23186787)
71. Galbraith CG, Yamada KM, Sheetz MP (2002) The relationship between force and focal complex development. J Cell Biol 159:695-705
72. Giannone G, Jiang G, Sutton DH, Critchley DR, Sheetz MP (2003) Talin1 is critical for force-dependent reinforcement of initial integrin-cytoskeleton bonds but not tyrosine kinase activation. J Cell Biol 163:409-419 (Pubitemid 37363140)
73. von Wichert G, Jiang G, Kostic A, De Vos K, Sap J, Sheetz MP (2003) Rptp-alpha acts as a transducer of mechanical force on alphav/beta3-integrin- cytoskeleton linkages. J Cell Biol 161:143-153 (Pubitemid 36459087)
74. Choquet D, Felsenfeld DP, Sheetz MP (1997) Extracellular matrix rigidity causes strengthening of integrin-cytoskeleton linkages. Cell 88:39-48 (Pubitemid 27180329)
75. Zhao XH, Laschinger C, Arora P, Szaszi K, Kapus A, McCulloch CA (2007) Force activates smooth muscle alpha-actin promoter activity through the rho signaling pathway. J Cell Sci 120:1801-1809 (Pubitemid 46930418)
76. Yeung T, Georges PC, Flanagan LA, Marg B, Ortiz M, Funaki M, Zahir N, Ming W, Weaver V, Janmey PA (2005) Effects of substrate stiffness on cell morphology, cytoskeletal structure, and adhesion. Cell Motil Cytoskeleton 60:24-34 (Pubitemid 40066224)
77. Zaman MH, Trapani LM, Sieminski A, MacKellar D, Gong H, Kamm RD, Wells A, Lauffenburger DA, Matsudaira P (2006) Migration of tumor cells in 3d matrices is governed by matrix stiffness along with cell-matrix adhesion and proteolysis. PNAS 103:10889-10894 (Pubitemid 44148391)
78. Alexander NR, Branch KM, Iwueke IC, Guelcher SA, Weaver AM (2008) Extracellular matrix rigidity promotes invadopodia activity. Curr Biol 18:1295-1299
79. Engler AJ, Sen S, Sweeney HL, Discher DE (2006) Matrix elasticity directs stem cell lineage specification. Cell 126:677-689 (Pubitemid 44233625)
80. Enderling H, Alexander NR, Clark E, Branch KM, Estrada L, Crooke C, Jourquin J, Lobdell N, Zaman MH, Guelcher SA, Anderson A, Weaver AM (2008) Dependence of invadopodia function on collagen fiber spacing and crosslinking: computational modeling and experimental evidence. Biophys J 95:2203-2218
81. Smith KE, Hyzy SL, Sunwoo M, Gall KA, Schwartz Z, Boyan BD (2010) The dependence of mg63 osteoblast responses to (meth)acrylate-based networks on chemical structure and stiffness. Biomaterials 31:6131-6141
82. Khatiwala CB, Kim PD, Peyton SR, Putnam AJ (2009) Ecm compliance regulates osteogenesis by influencing mapk signaling downstream of rhoa and rock. J Bone Miner Res 24:886-898
83. Butcher DT, Alliston T, Weaver VM (2009) A tense situation: forcing tumour progression. Nat Rev Cancer 9:108-122
84. Guelcher SA, Dumas J, Srinivasan A, Didier JE, Hollinger JO (2008) Synthesis, mechanical properties, biocompatibility, and biodegradation of polyurethane networks from lysine polyisocyanates. Biomaterials 29:1762-1775
85. Gibson LJ, Ashby MF (1997) Cellular solids: structure and properties. Cambridge University Press, Cambridge
86. Kang Y, Siegel PM, Shu W, Drobnjak M, Kakonen SM, Cordón- Cardo C, Guise TA, Massague J (2003) A multigenic program mediating breast cancer metastasis to bone. Cancer Cell 3:537-549 (Pubitemid 36808649)
87. Huang JH, Peng XL, Xiong CY, Fang J (2011) Influence of substrate stiffness on cell-substrate interfacial adhesion and spreading: a mechano-chemical coupling model. J Coll Interfac Sci 355:503-508
88. Bell GI (1978) Models for the specific adhesion of cells to cells. Science 200:618-627
89. Bershadsky AD, Balaban NQ, Geiger B (2003) Adhesiondependent cell mechanosensitivity. Annu Rev Cell Dev Biol 19:677-695
90. Desgrosellier JS, Cheresh DA Integrins in cancer: biological implications and therapeutic opportunities. Nat Rev Cancer 10:9-22
91. Engleman VW, Nickols GA, Ross FP, Horton MA, Griggs DW, Settle SL, Ruminski PG, Teitelbaum SL (1997) A peptidomimetic antagonist of the alpha(v)beta3 integrin inhibits bone resorption in vitro and prevents osteoporosis in vivo. J Clin Invest 99:2284-2292 (Pubitemid 27203787)
92. Galliher AJ, Schiemann WP (2006) Beta3 integrin and src facilitate transforming growth factor-beta mediated induction of epithelial-mesenchymal transition in mammary epithelial cells. Breast Canc Res 8:R42
93. Matthews BD, Overby DR, Mannix R, Ingber DE (2006) Cellular adaptation to mechanical stress: role of integrins, rho, cytoskeletal tension and mechanosensitive ion channels. J Cell Sci 119:508-518
94. Wang Y, Botvinick EL, Zhao Y, Berns MW, Usami S, Tsien RY, Chien S (2005) Visualizing the mechanical activation of src. Nature 434:1040-1045 (Pubitemid 40586054)
95. Sawada Y, Tamada M, Dubin-Thaler BJ, Cherniavskaya O, Sakai R, Tanaka S, Sheetz MP (2006) Force sensing by mechanical extension of the src family kinase substrate p130cas. Cell 127:1015-1026 (Pubitemid 44803062)
96. Huveneers S, Danen EH (2009) Adhesion signaling - crosstalk between integrins, src and rho. J Cell Sci 122:1059-1069
97. Harms ea (2004) A small molecule antagonist of the alphavbeta3 integrin suppresses mda-mb-435 skeletal metastasis. Clin Exp Met 21:119-128
98. Zhao YBR, Treilleux I, Pujuguet P, Peyruchaud O, Baron R (2007) Tumor alphavbeta3 integrin is a therapeutic target for breast cancer bone metastases. Cancer Res 67:5821-5830 (Pubitemid 46985016)
99. Myoui ANR, Williams PJ, Hiraga T, Tamura D, Michigami T et al (2003) C-src tyrosine kinase activity is associated with tumor colonization in bone and lung in an animal model of human breast cancer metastasis. Cancer Res 63:5028-5033 (Pubitemid 37022641)
100. Duband JL, Nuckolls GH, Ishihara A, Hasegawa T, Yamada KM, Thiery JP, Jacobson K (1988) Fibronectin receptor exhibits high lateral mobility in embryonic locomoting cells but is immobile in focal contacts and fibrillar streaks in stationary cells. J Cell Biol 107:1385-1396
101. Felsenfeld DP, Schwartzberg PL, Venegas A, Tse R, Sheetz MP (1999) Selective regulation of integrin-cytoskeleton interactions by the tyrosine kinase src. Nat Cell Biol 1:200-206 (Pubitemid 129500938)
102. Zhang X, Jiang G, Cai Y, Monkley SJ, Critchley DR, Sheetz MP (2008) Talin depletion reveals independence of initial cell spreading from integrin activation and traction. Nat Cell Biol 10:1062-1068
103. Galliher AJSW (2006) Beta3 integrin and src facilitate transforming growth factor beta mediated induction of epithelialmesenchumal transition in mammary epithelial cells. Breast Cancer Res 8:R42
104. Gui GP, Wells CA, Yeomans P, Jordan SE, Vinson GP, Carpenter R (1996) Integrin expression in breast cancer cytology: a novel predictor of axillary metastasis. Eur J Surg Oncol 22:254-258 (Pubitemid 26229675)
105. Mizejewski GJ (1999) Role of integrins in cancer: survey of expression patterns. Proc Soc Exp Biol Med 222:124-138
106. Shane E Evolving data about subtrochanteric fractures and bisphosphonates. N Engl J Med 362:1825-1827
107. Coleman R, Woodward E, Brown J, Cameron D, Bell R, Dodwell D, Keane M, Gil M, Davies C, Burkinshaw R, Houston SJ, Grieve RJ, Barrett-Lee PJ, Thorpe H (2011) Safety of zoledronic acid and incidence of osteonecrosis of the jaw (onj) during adjuvant therapy in a randomised phase iii trial (azure: Big 01-04) for women with stage ii/iii breast cancer. Breast Cancer Res Treat
108. Black DM, Kelly MP, Genant HK, Palermo L, Eastell R, Bucci- Rechtweg C, Cauley J, Leung PC, Boonen S, Santora A, de Papp A, Bauer DC (2010) Bisphosphonates and fractures of the subtrochanteric or diaphyseal femur. N Engl J Med 362:1761-1771
109. McClung MR (2006) Inhibition of rankl as a treatment for osteoporosis: preclinical and early clinical studies. Curr Osteoporos Rep 4:28-33 (Pubitemid 44623945)
110. Gonzalez-Suarez E, Jacob AP, Jones J, Miller R, Roudier-Meyer MP, Erwert R, Pinkas J, Branstetter D, Dougall WC (2010) Rank ligand mediates progestin-induced mammary epithelial proliferation and carcinogenesis. Nature 468:103-107
111. Biswas S, Guix M, Rinehart C, Dugger TC, Chytil A, Moses HL, Freeman ML, Arteaga CL (2007) Inhibition of tgf-beta with neutralizing antibodies prevents radiation-induced acceleration of metastatic cancer progression. J Clin Invest 117:1305-1313 (Pubitemid 46718418)
112. Ganapathy V, Ge R, Grazioli A, Xie W, Banach-Petrosky W, Kang Y, Lonning S, McPherson J, Yingling JM, Biswas S, Mundy GR, Reiss M (2010) Targeting the transforming growth factor-beta pathway inhibits human basal-like breast cancer metastasis. Mol Cancer 9:122
113. Mohammad KS, Javelaud D, Fournier PG, Niewolna M, McKenna CR, Peng XH, Duong V, Dunn LK, Mauviel A, Guise TA (2010) The transforming growth factor-{beta} receptor i kinase inhibitor sd-208 reduces the development and progression of melanoma bone metastases. Cancer Res
114. Edwards JR, Nyman JS, Lwin ST, Moore MM, Esparza J, O'Quinn EC, Hart AJ, Biswas S, Patil CA, Lonning S, Mahadevan-Jansen A, Mundy GR (2010) Inhibition of tgf-β signaling by 1d11 antibody treatment increases bone mass and quality in vivo. J Bone Miner Res 25:2419-2426
115. Mohammad KS, Chen CG, Balooch G, Stebbins E, McKenna CR, Davis H, Niewolna M, Peng XH, Nguyen DH, Ionova- Martin SS, Bracey JW, Hogue WR, Wong DH, Ritchie RO, Suva LJ, Derynck R, Guise TA, Alliston T (2009) Pharmacologic inhibition of the tgf-beta type i receptor kinase has anabolic and anti-catabolic effects on bone. PLoS One 4:e5275
116. Tan AR, Alexe G, Reiss M (2009) Transforming growth factorbeta signaling: emerging stem cell target in metastatic breast cancer? Breast Canc Res Treat 115:453-495
117. Barman SA, Zhu S, White RE (2009) Rhoa/rho-kinase signaling: a therapeutic target in pulmonary hypertension. Vasc Health Risk Manag 5:663-671
118. Olson MF (2008) Applications for rock kinase inhibition. Curr Opin Cell Biol 20:242-248
119. Summy JM, Gallick GE (2006) Treatment for advanced tumors: Src reclaims center stage. Clin Canc Res 12:1398-1401
120. Boyce BF, Xing L, Yao Z, Yamashita T, Shakespeare WC, Wang Y, Metcalf CA 3rd, Sundaramoorthi R, Dalgarno DC, Iuliucci JD, Sawyer TK (2006) Src inhibitors in metastatic bone disease. Clin Canc Res 12:6291s-6295s (Pubitemid 44703805)
121. Desgrosellier JSCD (2010) Integrins in cancer: biological implications and therapeutic opportunities. Nat Rev Cancer 10:9-22
122. Ruppender NS, Merkel AR, Guelcher SA (Submitted) Bone matrix rigidity stimulates signaling through αvβ3, src and mapk to induce the expression of pthrp in osteolytic tumor cells
123. Brooks PC, Stromblad S, Klemke R, Visscher D, Sarkar FH, Cheresh DA (1995) Antiintegrin alpha v beta 3 blocks human breast cancer growth and angiogenesis in human skin. J Clin Invest 96:1815-1822
124. Moschos SJ, Sander CA, Wang W, Reppert SL, Drogowski LM, Jukic DM, Rao UN, Athanassiou C, Buzoianu M, Mandic M, Richman L, McKinney L, Leininger J, Tice DA, Hammershaimb L, Kirkwood JM (2010) Pharmacodynamic (phase 0) study using etaracizumab in advanced melanoma. J Immunother 33:316-325
125. O'Day SJ, Pavlick AC, Albertini MR, Hamid O, Schalch H, Lang Z, Ling J, Mata M, Reddy M, Foster B (2011) Clinical and pharmacologic evaluation of two dose levels of intetumumab (cnto 95) in patients with melanoma or angiosarcoma. Invest New Drugs
126. Stupp R, Hegi ME, Neyns B, Goldbrunner R, Schlegel U, Clement PM, Grabenbauer GG, Ochsenbein AF, Simon M, Dietrich PY, Pietsch T, Hicking C, Tonn JC, Diserens AC, Pica A, Hermisson M, Krueger S, Picard M, Weller M (2010) Phase i/iia study of cilengitide and temozolomide with concomitant radiotherapy followed by cilengitide and temozolomide maintenance therapy in patients with newly diagnosed glioblastoma. J Clin Oncol 28:2712-2718
127. Lauth M, Bergstrom A, Shimokawa T, Toftgard R (2007) Inhibition of gli-mediated transcription and tumor cell growth by small-molecule antagonists. Proc Natl Acad Sci USA 104:8455-8460 (Pubitemid 47175509)
128. Galliher AJ, Schiemann WP (2007) Src phosphorylates tyr284 in tgf-beta type ii receptor and regulates tgf-beta stimulation of p38 mapk during breast cancer cell proliferation and invasion. Cancer Res 67:3752-3758 (Pubitemid 46762161)